Deep Dives
New studies, trials, and what they mean.
A new class of Alzheimer’s drugs can modestly slow decline, but APOE4 carriers, especially those with two copies, face higher rates of a key side effect.
The landmark FINGER study tested whether a combined lifestyle program could protect cognition in at-risk older adults. What it found, and why it matters for carriers.
For years, confirming Alzheimer’s biology meant a spinal tap or a PET scan. Blood tests are starting to change that, with big implications and real caveats.
What if you could treat the gene itself? Researchers are exploring ways to target APOE directly. A grounded look at the strategies and how early they still are.
Carriers are sought-after for prevention research. Why you might consider a trial, how to find one, and what to know before you enroll.